Glucocorticoid receptor (GR) proteins that enter the nucleus after binding hormone ligand in v-mos-transformed cells, are rapidly depleted from that compartment and subsequently redistributed to the cytoplasm. GRs that have acquired this property (i.e. inefficient nuclear re-entry) in hormone treated v-mos-transformed cells can be classified as desensitized, since they cannot re-enter the after secondary hormone treatments. Nuclear entry of ligand-bound GRs is not by itself sufficient to desensitize GRs in v- mos-transformed cells, as antagonist-bound receptors are efficiently retained within the nucleus and not redistributed to the cytoplasm. Thus, the action of v-mos oncoproteins appear to be restricted to GR proteins that are recycling between the nuclear and cytoplasmic compartment. The long term goals of this proposal are to uncover the mechanisms responsible for this oncoprotein-mediated alteration in the subcellular compartmentalization of this signal transducing protein. In particular, we hope to reveal the molecular and biochemical basis for the apparent block in GR recycling that occurs in v-mos-transformed cells. Since GR dephosphorylation is a critical component of proposed receptor recycling pathways, we will examine the phosphorylation state of desensitized receptors by 2-dimensional mapping of phosphotryptic peptides generated from 32P-labeled immunopurified receptors. Qualitative and/or quantitative differences in the phosphorylation profile of GRs that are unable to recycle may be revealed. The effects of okadaic acid, a specific protein phosphatase type 1 and 2A inhibitor, on recycling and phosphorylation of Grs in vivo will be examined by indirect immunofluorescence and 2- dimensional tryptic mapping, respectively. Purified protein phosphatases types 1 and 2A will be used in vitro to dephosphorylate in vivo 32P-labeled immunopurified GRs and specific sites of PP1 and PP2A dephosphorylation identified by 2-dimensional tryptic mapping. In this way dephosphorylation of specific phosphoserine residues within the GR that are associated with a recycling pathway may be identified. Immunoprecipitations and glycerol gradient sedimentation analyses will be used to in order to determine whether other cellular factors are associated with desensitized receptors. We will also ascertain whether, nuclear- and DNA-binding activity of desensitized receptors can be recovered in vitro through dissociation of putative desensitized receptor-multiprotein complexes by high salt, elevated temperatures, and/or dephosphorylation with purified PP1 and PP2A. Finally, we will use a novel genetic selection scheme to screen for potential GR, v-mos oncoprotein phosphatase, and cellular mutations that lead to the reversal of receptor desensitization. Through these studies we hope to gain a better understanding of how regulated modification of a signal transducing protein influences its subcellular compartmentalization and association with ancillary factors that modify its function.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA043037-06
Application #
3184890
Study Section
Endocrinology Study Section (END)
Project Start
1986-07-01
Project End
1995-11-30
Budget Start
1992-12-01
Budget End
1993-11-30
Support Year
6
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of Pittsburgh
Department
Type
Schools of Arts and Sciences
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Dekelbab, Bassem H; Witchel, Selma F; DeFranco, Donald B (2007) TNF-alpha and glucocorticoid receptor interaction in L6 muscle cells: a cooperative downregulation of myosin heavy chain. Steroids 72:705-12
Rasar, Melissa; DeFranco, Donald B; Hammes, Stephen R (2006) Paxillin regulates steroid-triggered meiotic resumption in oocytes by enhancing an all-or-none positive feedback kinase loop. J Biol Chem 281:39455-64
Heitzer, M D; DeFranco, D B (2006) Mechanism of action of Hic-5/androgen receptor activator 55, a LIM domain-containing nuclear receptor coactivator. Mol Endocrinol 20:56-64
Heitzer, Marjet D; DeFranco, Donald B (2006) Hic-5/ARA55, a LIM domain-containing nuclear receptor coactivator expressed in prostate stromal cells. Cancer Res 66:7326-33
Wang, Xinjia; DeFranco, Donald B (2005) Alternative effects of the ubiquitin-proteasome pathway on glucocorticoid receptor down-regulation and transactivation are mediated by CHIP, an E3 ligase. Mol Endocrinol 19:1474-82
Guerrero-Santoro, Jennifer; Yang, Lan; Stallcup, Michael R et al. (2004) Distinct LIM domains of Hic-5/ARA55 are required for nuclear matrix targeting and glucocorticoid receptor binding and coactivation. J Cell Biochem 92:810-9
Pratt, William B; Galigniana, Mario D; Harrell, Jennifer M et al. (2004) Role of hsp90 and the hsp90-binding immunophilins in signalling protein movement. Cell Signal 16:857-72
Wang, Xinjia; Pongrac, Julie L; DeFranco, Donald B (2002) Glucocorticoid receptors in hippocampal neurons that do not engage proteasomes escape from hormone-dependent down-regulation but maintain transactivation activity. Mol Endocrinol 16:1987-98
Yang, L; Guerrero, J; Hong, H et al. (2000) Interaction of the tau2 transcriptional activation domain of glucocorticoid receptor with a novel steroid receptor coactivator, Hic-5, which localizes to both focal adhesions and the nuclear matrix. Mol Biol Cell 11:2007-18
Liu, J; DeFranco, D B (2000) Protracted nuclear export of glucocorticoid receptor limits its turnover and does not require the exportin 1/CRM1-directed nuclear export pathway. Mol Endocrinol 14:40-51

Showing the most recent 10 out of 34 publications